National calls to action supporting integration of radioligand therapy into cancer care

As the global burden of cancer continues to rise, there is growing recognition of the need for innovative, targeted therapies that can improve outcomes and quality of life for people with the disease. Radioligand therapy – a precision oncology treatment that delivers targeted radiation to cancer cells while minimising harm to surrounding tissue – has shown significant promise in enhancing survival and slowing disease progression.

However, the successful integration of radioligand therapy into routine care depends on health systems being adequately prepared – with the right infrastructure, policies and workforce in place to support sustainable delivery. In response to this challenge, The Health Policy Partnership (HPP) has launched four national calls to action to help realise the potential of this treatment in diverse health systems.

The latest publications, for Malaysia and Saudi Arabia, follow earlier reports on Taiwan and the United Arab Emirates. Each call to action is based on insights from experts in oncology, nuclear medicine and health policy; and each outlines the principal barriers to implementing radioligand therapy and provides recommendations for policymakers.

These reports are the latest in HPP’s ongoing work on health system readiness for radioligand therapy and other innovative treatments. The publications aim to support governments and healthcare leaders in paving the way for innovations in cancer care to reach the people who need them most.

For more information, please visit the project page.